Ironjustic
Thu, Aug-16-07, 06:16
Do you think this patient would have been cured .. IF .. they
had removed the iron .. FIRST .. without ever HAVING to do a
marrow transplantation .. ?
The second article shows .. in anemia .. BY doing JUST that
they accidentally / paradoxically .. **cured** .. that is ..
**cured** the .. patient.
"unexpected reduction in blood transfusion requirement,
ultimately resulting in long-lasting transfusion-free
survival. "
**Cured**
Hemoglobin. 2006;30(1):131-7. Links Iron burden and liver
fibrosis decrease during a long-term phlebotomy program and
iron chelating treatment after bone marrow transplantation.
Meo A, Ruggeri A, La Rosa MA, Zangh=EC L, Morabito N, Duca L.
Paediatric Department, "G. Martino" Policlinico University of
Messina, Messina, Italy. ameo@unime.it
In this retrospective study, we report the results of the
association of a combined phlebotomy program and chelation in
hereditary sideroblastic anemia (HSA) to reduce iron overload
after bone marrow transplantation (BMT). A male HSA patient,
not responding to pyridoxine treatment, was submitted to
successful allogeneic BMT. As there was a persistence of a
tissue iron overload, a regular phlebotomy program was started
followed by chelation. A significant decrease of iron burden
was obtained using a combined treatment with deferoxamine
(DFO) and deferiprone (L1) in addition to the phlebotomy
program. A 10-year follow-up shows a marked decrease in the
concentration of serum ferritin, non-transferrin-bound iron
(NTBI), liver iron and normal hemoglobin (Hb), which allows
the patient to reach and maintain a good quality of life.
PMID: 16540426 [PubMed - indexed for MEDLINE]
---------------------------------------------------------
----------
<<snip>> resulting in long-lasting transfusion-free
survival <<snip>>
Correction of anemia in a transfusion-dependent patient with
primary myelofibrosis receiving iron chelation therapy with
deferasirox (Exjade=AE, ICL670) Authors: Di Tucci, Anna
Angela1; Murru, Roberta1; Alberti, Daniele2; Rabault,
Bertrand2; Deplano, Simona1; Angelucci, Emanuele1
Source: European Journal of Haematology, Volume 78, Number 6,
June 2007, pp. 540-542(3)
Publisher: Blackwell Publishing Abstract:
Transfusional iron overload in patients with chronic anemias
can result in multiple organ failure. Experience in the
management of iron overload in patients with myelodysplastic
syndromes is limited, as many do not receive chelation therapy
due to short-life expectancy and the difficulties associated
with the administration of the current reference standard
chelator, deferoxamine. There have, however, been some reports
of reduced transfusion requirement associated with chelation
therapy in patients with myelodysplastic syndromes and
myelofibrosis. Here, we discuss a patient with primary
myelofibrosis and related transfusion-dependent anemia who
received chelation therapy with the once-daily oral iron
chelator, deferasirox. In addition to the reduced iron levels,
the patient demonstrated an unexpected reduction in blood
transfusion requirement, ultimately resulting in long-lasting
transfusion-free survival. Keywords: myelofibrosis; iron
overload; chelation
Document Type: Research article
DOI: 10.1111/j.1600-0609.2007.00840.x
Affiliations: 1: Unit=E0 Operativa Ematologia e Centro
Trapianti Midollo Osseo, Ospedale Oncologico `Armando
Businco', Cagliari, Italy 2: Novartis Pharma AG, Basel,
Switzerland
Who loves ya. Tom
Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com
Man Is A Herbivore! http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING http://tinyurl.com/zk9fk
had removed the iron .. FIRST .. without ever HAVING to do a
marrow transplantation .. ?
The second article shows .. in anemia .. BY doing JUST that
they accidentally / paradoxically .. **cured** .. that is ..
**cured** the .. patient.
"unexpected reduction in blood transfusion requirement,
ultimately resulting in long-lasting transfusion-free
survival. "
**Cured**
Hemoglobin. 2006;30(1):131-7. Links Iron burden and liver
fibrosis decrease during a long-term phlebotomy program and
iron chelating treatment after bone marrow transplantation.
Meo A, Ruggeri A, La Rosa MA, Zangh=EC L, Morabito N, Duca L.
Paediatric Department, "G. Martino" Policlinico University of
Messina, Messina, Italy. ameo@unime.it
In this retrospective study, we report the results of the
association of a combined phlebotomy program and chelation in
hereditary sideroblastic anemia (HSA) to reduce iron overload
after bone marrow transplantation (BMT). A male HSA patient,
not responding to pyridoxine treatment, was submitted to
successful allogeneic BMT. As there was a persistence of a
tissue iron overload, a regular phlebotomy program was started
followed by chelation. A significant decrease of iron burden
was obtained using a combined treatment with deferoxamine
(DFO) and deferiprone (L1) in addition to the phlebotomy
program. A 10-year follow-up shows a marked decrease in the
concentration of serum ferritin, non-transferrin-bound iron
(NTBI), liver iron and normal hemoglobin (Hb), which allows
the patient to reach and maintain a good quality of life.
PMID: 16540426 [PubMed - indexed for MEDLINE]
---------------------------------------------------------
----------
<<snip>> resulting in long-lasting transfusion-free
survival <<snip>>
Correction of anemia in a transfusion-dependent patient with
primary myelofibrosis receiving iron chelation therapy with
deferasirox (Exjade=AE, ICL670) Authors: Di Tucci, Anna
Angela1; Murru, Roberta1; Alberti, Daniele2; Rabault,
Bertrand2; Deplano, Simona1; Angelucci, Emanuele1
Source: European Journal of Haematology, Volume 78, Number 6,
June 2007, pp. 540-542(3)
Publisher: Blackwell Publishing Abstract:
Transfusional iron overload in patients with chronic anemias
can result in multiple organ failure. Experience in the
management of iron overload in patients with myelodysplastic
syndromes is limited, as many do not receive chelation therapy
due to short-life expectancy and the difficulties associated
with the administration of the current reference standard
chelator, deferoxamine. There have, however, been some reports
of reduced transfusion requirement associated with chelation
therapy in patients with myelodysplastic syndromes and
myelofibrosis. Here, we discuss a patient with primary
myelofibrosis and related transfusion-dependent anemia who
received chelation therapy with the once-daily oral iron
chelator, deferasirox. In addition to the reduced iron levels,
the patient demonstrated an unexpected reduction in blood
transfusion requirement, ultimately resulting in long-lasting
transfusion-free survival. Keywords: myelofibrosis; iron
overload; chelation
Document Type: Research article
DOI: 10.1111/j.1600-0609.2007.00840.x
Affiliations: 1: Unit=E0 Operativa Ematologia e Centro
Trapianti Midollo Osseo, Ospedale Oncologico `Armando
Businco', Cagliari, Italy 2: Novartis Pharma AG, Basel,
Switzerland
Who loves ya. Tom
Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com
Man Is A Herbivore! http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING http://tinyurl.com/zk9fk